KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4.

Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Shintaro Hirata, Kunihiro Yamaoka, Bernard G Combe, Peter Nash, Mark Genovese, Alena Pechonkina, Jie Liu, Akira Kondo, Haruhiko Fukada, Francesco De Leonardis, Tsutomu Takeuchi

Mod Rheumatol 35(3) 425-433

PMID39506562
PMCID-
DOI10.1093/mr/roae099
发表日期2024-11-07
摘要

摘要

OBJECTIVES: The aim of this article is to describe the safety and efficacy of filgotinib 200 mg (FIL200) or FIL 100 mg (FIL100) in Japanese patients with rheumatoid arthritis in a long-term extension (NCT03025308). METHODS: Patients who completed any of three parent studies (NCT02889796: inadequate response to methotrexate; NCT02873936: inadequate response to biologic disease-modifying antirheumatic drugs; NCT02886728: methotrexate-naïve) without rescue therapy could enter the long-term extension; patients taking FIL continued their dosage, and those who received comparators were rerandomised to FIL200 or FIL100. This analysis includes Week 156 interim results. RESULTS: Among Japanese patients, 110 received FIL200, and 97 received FIL100. Mean (SD) FIL200 and FIL100 exposure was 157.0 (51.49) and 156.0 (52.45) weeks. The exposure-adjusted incidence rates (95% confidence interval) for FIL200/FIL100 were 2.7 (1.4, 5.2)/2.4 (1.2, 5.1) for herpes zoster, 0.9 (0.3, 2.8)/1.0 (0.3, 3.2) for malignancy (excluding nonmelanoma skin cancer), and 0.6 (0.2, 2.4)/0.3 (0.0, 2.4) for major adverse cardiovascular events. More patients receiving FIL200 with prior FIL200 exposure achieved clinical remission vs other groups (including Clinical Disease Activity Index remission in 40% vs ≤27% at Week 156). CONCLUSIONS: FIL200 and FIL100 were generally well tolerated by Japanese patients, without new, unexpected adverse events.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。